2 files

PF 06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers

posted on 06.07.2020 by Shahrzad Moosavi, Troy Borema, Reginald Ewesuedo, Stuart Harris, Jeffrey Levy, Thomas B. May, Martin Summers, Jeffrey S. Thomas, Jeffrey Zhang, Hsuan-Ming Yao

The above summary slide and plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.